In June 2025, the Netherlands became the first country to fully reimburse whole genome sequencing for cancer patients, turning a research privilege into standard care overnight. The decision doubled actionable biomarker findings and expanded access to patients who previously had none. Europe is watching closely, and several countries are already moving to follow.
What Reimbursement Means for Patients
Before June 2025, WGS was available mainly through clinical trials or at significant personal expense. Only around 1,100 patients per year received it across 30 hospitals in the Netherlands, a fraction of those who could benefit. The reimbursement decision changed that for every eligible oncology patient in the country.
The practical impact is real. WGS doubles the number of patients with actionable biomarkers compared to conventional diagnostic approaches. That means faster treatment matching, broader access to precision clinical trials, and earlier identification of targeted therapies.
Equity is another major shift. Access to genomic profiling was previously skewed toward urban academic centers. Patients in rural areas or with fewer financial resources were far less likely to receive WGS. Reimbursement removed that barrier.
Ripple Effects Beyond Dutch Borders
Belgium, Germany, and France are now evaluating similar WGS reimbursement frameworks, watching Dutch implementation data for clinical and economic outcomes. Europe’s DNA sequencing market is projected to reach USD 7.89 billion by 2034, growing at a 13.32% annual rate from USD 2.90 billion in 2026. Reimbursement policy accelerates adoption far more effectively than technology availability alone. The Dutch model, which links diagnostics, treatment access, and real-world evidence through its Drug Access Protocol platform, offers a practical blueprint other nations can adapt rather than build from scratch.
